Argentina: mAbxience
Buenos Aires

History

Founded in 2008 by a team of scientists with over 35 years’ experience in the development and production of biopharmaceuticals, with expert knowledge of GMPs * and regulatory pathways.
*GMP: (Good Manufacturing Practices)

Extensive experience in the development and production of interferon alfa, filgrastim, molgramostim, interleukin 2, erythropoietin, interferon beta and hepatitis B vaccine, for national and export markets.

 

It benefits from a young, multidisciplinary and international team, committed to the emerging field of biosimilars. Furthermore, mAbxience is supporting the training of local young people in the field of biotechnology.

 

Facilities

In 2012, mAbxience Buenos Aires became the first monoclonal antibody production facility in South America, with single-use technology, and two years later, in 2014, the first plant with a monoclonal antibody biosimilar produced integrally in Argentina.

 
Regulatory agencies approvals

mAbxience Buenos Aires plant has several GMP certificates from several international agencies, such as COFEPRIS (Mexico), ANMAT (Argentina), counting also with Turkey and Colombia, among others.